Johnson & Johnson Launches Pioneering Study on FcRn Blockers for Myasthenia Gravis

Johnson & Johnson launches the EPIC study to compare IMAAVY with efgartigimod in treating patients with Myasthenia gravis, marking a significant advancement in FcRn blockers research.

• The Phase 3b open-label trial will enroll adults with Myasthenia gravis who have not previously received an FcRn blocker, aiming to assess efficacy and safety outcomes.
• This head-to-head study will also include a treatment-switch arm, allowing patients currently on efgartigimod to switch to IMAAVY, enhancing understanding of autoantibody impacts.
• Conducted in the United States, the trial focuses on the role of Immunoglobulin G and the neonatal Fc receptor in the mechanisms of Myasthenia gravis treatment.